Making Medicine

Hosts discuss Faster Clinical Trials Act, European MFN fallout, and October biotech VC data

17 min Listen to the original Episode page
BiotechClinical TrialsRegulatory PolicyVenture CapitalInternational Markets

Summary

The hosts introduce the Faster Clinical Trials Act, a bipartisan bill aiming to modernize clinical trials using AI and genomic evidence. They analyze the fallout of Maximum Fairness in Pricing (MFN) in Europe, noting Roche's delayed approval and Novartis's potential bypass of government reimbursement. The episode highlights Japan's pricing reform efforts and recent FDA approvals for Asahi Kasei and GSK. Finally, they review October venture capital data, showing Massachusetts leading in early-stage biotech investments.

Episode sections

  1. 0:00 – 2:45

    Intro and Agenda

    Hosts introduce the podcast's disclaimer and outline the episode's topics, including the Faster Clinical Trials Act, MFN fallout in Europe, Japan pricing reforms, FDA approvals, and October venture capital data.

  2. 2:45 – 7:25

    Faster Clinical Trials Act

    The hosts discuss a new bipartisan bill introduced by Reps. Jake Auchincloss and Morgan Griffith to modernize clinical trials, reduce delays, and integrate research into everyday care using AI and genomic evidence.

  3. 7:25 – 11:49

    MFN Fallout in Europe

    Roche delayed European approval for a breast cancer pill, and Novartis may bypass government reimbursement in Europe. The hosts argue this threatens U.S. innovation incentives by shrinking the global revenue pie.

  4. 11:49 – 13:09

    Japan Pricing Reform

    Hirobumi Niki of Japan's ruling party called for overhauling cost-effectiveness assessments to value innovation rather than just cutting prices, a shift the hosts view as encouraging for the biotech ecosystem.

  5. 13:09 – 14:18

    FDA Approvals

    Two notable October approvals were highlighted: Hovilpre from Asahi Kase Therapeutics for HSV and HIPSAGO from GSK for chronic hepatitis B, both representing significant therapeutic advances.

  6. 14:18 – 15:39

    October Venture Capital Data

    October saw 50 early-stage biotech investments totaling $1.14 billion, with Massachusetts leading in total capital raised, followed by California and New York.

  7. 15:39 – 16:58

    Upcoming Events and Conclusion

    The hosts announce their attendance at the Jefferies London Healthcare Conference and encourage listeners to participate in an investor survey to inform new Congress members about biotech investment trends.

Claims worth verifying

The Faster Clinical Trials Act was introduced by Representatives Jake Auchincloss (Democrat from Massachusetts) and Morgan Griffith (Republican from Virginia).

Unidentified speaker ·2:45

How to verify: Search U.S. Congress legislative records for the bill introduction by these specific representatives and their stated party/state affiliations.

Roche pushed back its plans to seek European approval for a breast cancer pill, now planning to begin discussions with European regulators in 2027.

Unidentified speaker ·7:58

How to verify: Check press releases from Roche or news reports from Endpoints News regarding the specific delay of the European filing timeline.

Novartis CEO stated the company may launch new medicines through private insurance or directly to paying patients in Europe, bypassing traditional government reimbursement negotiations.

Unidentified speaker ·8:27

How to verify: Review transcripts of Novartis earnings calls or official statements from Novartis regarding their European launch strategy and CEO comments.

Hirobumi Niki leads health policy for Japan's ruling Liberal Democratic Party and called for abolishing Japan's off-year drug price revisions.

Unidentified speaker ·11:52

How to verify: Search for statements by Hirobumi Niki in Japanese political news or policy documents from the Liberal Democratic Party regarding drug pricing.

Asahi Kasei Therapeutics' treatment Hovilpre was approved by the FDA on October 9th for HSV.

Unidentified speaker ·13:26

How to verify: Check the FDA's official drug approval database or press releases from Asahi Kasei Therapeutics for the specific approval date and indication.

GSK's treatment HIPSAGO was approved by the FDA on October 20th for chronic hepatitis B.

Unidentified speaker ·13:46

How to verify: Check the FDA's official drug approval database or press releases from GSK for the specific approval date and indication.

In October, 50 early-stage biotech investments totaled approximately $1.14 billion.

Unidentified speaker ·14:33

How to verify: Review the Incubate or Making Medicine Podcast's published October venture capital report or database for the specific investment count and total capital raised.

Massachusetts led October investments with nearly $430 million across seven deals.

Unidentified speaker ·14:40

How to verify: Cross-reference the October venture capital data report with state-level investment summaries to verify the total capital and deal count for Massachusetts.

Massachusetts 5th district, represented by Catherine Clark, had nearly $200 million invested across two deals in October.

Unidentified speaker ·14:57

How to verify: Check the detailed congressional district-level breakdown in the October venture capital report to verify the specific dollar amount and deal count for MA-05.

Massachusetts 7th district, represented by Ayanna Pressley, had nearly $150 million invested in October.

Unidentified speaker ·15:07

How to verify: Check the detailed congressional district-level breakdown in the October venture capital report to verify the specific dollar amount for MA-07.

Do your own research

  • Verify the current legislative status and text of the Faster Clinical Trials Act introduced by Reps. Auchincloss and Griffith.
  • Review Roche's official press releases and regulatory filings regarding the delay of their breast cancer pill approval in Europe.
  • Analyze Novartis's recent earnings calls and investor presentations for details on European pricing strategies and reimbursement bypasses.
  • Check Japan's Ministry of Health, Labour and Welfare announcements regarding cost-effectiveness assessment reforms.
  • Examine FDA approval letters for Asahi Kasei Therapeutics' Hovilpre and GSK's HIPSAGO.
  • Review Crunchbase or PitchBook data for October 2024 early-stage biotech investment totals and geographic distribution.
  • Consult the Jefferies London Healthcare Conference agenda for speaker insights on biotech investment trends.
Full transcriptexpand
0:00
Unidentified speaker: At Making Medicine, we're reporting on the headlines, not making medical recommendations.
0:05
Unidentified speaker: For personal health questions, always ask your doctor.
0:08
Unidentified speaker: Nothing in this episode constitutes investment, financial, or legal advice.
0:13
Unidentified speaker: Consult your own advisors before making decisions.
0:16
Unidentified speaker: So if you zoom out, what does it all mean?
0:18
Unidentified speaker: For emerging biotech companies, clinical development is often the most expensive and time-consuming part of bringing a medicine to market.
0:25
Unidentified speaker: Making trials faster and more predictable could have enormous implications for how investors deploy capital and how far that capital goes.
0:33
Unidentified speaker: It's encouraging to see bipartisan recognition that FDA's modernization is essential to keeping American biotech competitive.
0:53
Unidentified speaker: We're recording on election day, so there'll be a lot to talk about in future episodes based on what happens today, but we don't quite have the results.
1:02
Unidentified speaker: And so we'll be looking at different issues on today's episode.
1:06
Unidentified speaker: We'll start with a new bipartisan bill to speed up clinical trials, some fresh warnings about how MFN pricing is shaping drug launches overseas, and some encouraging signs on pricing reform right on the heels of our trip to Japan.
1:20
Unidentified speaker: We'll cover two notable approvals in our FDA approvals corner, and we'll break down October's venture investment numbers.
1:26
Unidentified speaker: And finally, we'll tell you where to find us in London at Jeffree's later this month.
1:32
Unidentified speaker: Let's get into the show.
1:33
Unidentified speaker: We're recording this episode on Tuesday, November 3rd, or election day here in the United States.
1:38
Unidentified speaker: So by the time you listen when this drops on Thursday morning, voters will have decided the makeup of the next Congress.
1:45
Unidentified speaker: We won't spend time speculating about the results today, but the outcome will have important implications for federal biotech policy.
1:52
Unidentified speaker: As we've talked about on the show before, next year will be the consideration of PADUFA, PADUFA 8, that is, which really governs how the FDA and industry work together.
2:02
Unidentified speaker: We'll also hope that the new Congress, whoever's in charge, can bring some of the energy around FDA modernization that we'll talk about later in this episode.
2:10
Unidentified speaker: So we'll be back for a future episode breaking down those results.
2:14
Unidentified speaker: Should Democrats take control of one or both chambers, it probably means we'll be digging up our books on the IRA and seeing what policies they feel like need to be expanded, going back to the Biden administration.
2:26
Unidentified speaker: So no matter what, Incubate and the Making Medicine Podcast will be here educating these new lawmakers.
2:32
Unidentified speaker: There'll be so many new faces who aren't familiar with what it takes to make medicine.
2:38
Unidentified speaker: Speaking of carrying over FDA modernization into a new Congress, this Congress isn't quite done.
2:45
Unidentified speaker: As we briefly teased on the last episode, we've had the introduction on Capitol Hill of new legislation, the Faster Clinical Trials Act, from representatives Jake Akenkloss, a Democrat from Massachusetts, and Morgan Griffith, a Republican from Virginia.
3:00
Unidentified speaker: The goal of their legislation is straightforward: modernize how clinical trials are conducted in America, reduce unnecessary delays, and help new treatments reach patients faster.
3:09
Unidentified speaker: This all happens in the context of more and more clinical trials and clinical research services happening overseas.
3:16
Unidentified speaker: In their release, they jointly said, quote, America's fragmented and friction-filled clinical research enterprise has not kept pace with the speed of science, nor the investment by other nations.
3:28
Unidentified speaker: The difficulty of integrating clinical trials into U.S.
3:31
Unidentified speaker: sites of care has slowed down American development, testing, and approval.
3:36
Unidentified speaker: That's certainly something that'd be hard to disagree with when you look at the numbers.
3:40
Unidentified speaker: And that's why both policymakers, in a bipartisan way, have made a fairly comprehensive proposal.
3:46
Unidentified speaker: We won't go through the entire bill because there's a lot, but we wanted to call out five areas worth highlighting.
3:52
Unidentified speaker: The first is expanding access to clinical trials.
3:56
Unidentified speaker: The bill would establish a center for clinical trial innovation at FDA and build clinical trial networks that integrate research into everyday care, particularly in rural and underserved communities.
4:08
Unidentified speaker: The gap between those who need or would benefit potentially from a clinical trial and those who are actually able to find them is significant.
4:16
Unidentified speaker: The second thing the bill would look to do is reduce regulatory barriers.
4:20
Unidentified speaker: They do that by streamlining trial startup requirements, reducing duplicative reviews, and create a faster pathway for certain lower-risk phase one trials.
4:31
Unidentified speaker: Some of this is just common sense.
4:33
Unidentified speaker: In some drug development, we're not talking about safety or efficacy that could lead to the death of the patient.
4:39
Unidentified speaker: And so it makes sense in those places to explore phase one trials that are simply easier.
4:44
Unidentified speaker: That common sense theme comes throughout the bill.
4:47
Unidentified speaker: It's also evident in the next section, which covers modernizing drug development.
4:52
Unidentified speaker: The bill would encourage the use of artificial intelligence, or superintelligence, as some are calling it, using human-based models and alternatives to animal testing, while addressing common causes of FDA clinical holds.
5:04
Unidentified speaker: This builds off of a lot of lessons learned in other countries, particularly in Australia, where the benefit of in silico trial design is something that is heavily discussed.
5:14
Unidentified speaker: And the goal to get away from animals can lead to faster and cheaper drug development.
5:20
Unidentified speaker: The bill would also look to improve regulatory predictability, which we know on this show means everything to both the entrepreneurs in biotechs and the investors who back them.
5:29
Unidentified speaker: They would do this by strengthening the FDA's rare disease innovation hub, which would allow for more flexible clinical trials and improve international coordination and oversight.
5:38
Unidentified speaker: Rare disease is certainly somewhere where predictability of these alternative pathways has to be paramount.
5:46
Unidentified speaker: And while there have been a number of initiatives out of recent FDAs, those initiatives may not be enough to bank on.
5:52
Unidentified speaker: It's really statute that could make a meaningful difference.
5:55
Unidentified speaker: And finally, the bill would also build better evidence, would strengthen FDA's oncology center of excellence and expand the use of genomic evidence in cancer treatment and develop a national biobank connecting biological samples with health data.
6:10
Unidentified speaker: We know this data and the use of modern evidence is going to play a bigger picture, whether AI is in the picture or not.
6:17
Unidentified speaker: So if you zoom out, what does it all mean?
6:20
Unidentified speaker: For emerging biotech companies, clinical development is often the most expensive and time-consuming part of bringing a medicine to market.
6:27
Unidentified speaker: Making trials faster and more predictable could have enormous implications for how investors deploy capital and how far that capital goes.
6:36
Unidentified speaker: It's encouraging to see bipartisan recognition that FDA's modernization is essential to keeping American biotech competitive.
6:44
Unidentified speaker: We're looking forward to working closely with Representatives Griffith and Aachenkloss in the months ahead in places where the bill might need tweaks, guidance, or input from the investor community.
6:54
Unidentified speaker: But what we've said on this show before, and what's critically important, is that we take some of the energy that has been stirred up as part of the China and Coins conversation and carry it in to the energy that these two members of Congress are putting into reforming the FDA.
7:10
Unidentified speaker: The uniform position from almost anyone in the ecosystem is that in order for the U.S.
7:17
Unidentified speaker: to be more competitive, we have to modernize the FDA.
7:20
Unidentified speaker: And we hope this bill can be a vehicle to start the conversation that ultimately does that.
7:25
Unidentified speaker: As we teased on last week's episode, there's also some news not just about the FDA, but looking around the world on that other big policy, most favored nation, or MFN.
7:36
Unidentified speaker: We're starting to see some real-world examples of how MFN is reshaping the drug pricing conversation, which could limit patient access as well as impact investment into new medicines.
7:48
Unidentified speaker: The newsiest piece comes from our friends at Endpoints, who covered the Roche story, who recently pushed back its plans to seek European approval for a promising new breast cancer pill.
7:58
Unidentified speaker: The company had previously anticipated filing in Europe this year, but now plans to begin discussions with European regulators in 2027.
8:07
Unidentified speaker: Meanwhile, its U.S.
8:08
Unidentified speaker: regulatory timeline remains on track.
8:11
Unidentified speaker: Roche hasn't directly attributed that decision to MFN, citing the need for more mature clinical data, but it's exactly the kind of delayed European launch that industry observers have been warning about.
8:23
Unidentified speaker: Similarly, Novartis is considering an even more dramatic shift.
8:27
Unidentified speaker: Its CEO recently said the company may launch new medicines through private insurance or directly to paying patients in Europe bypassing traditional government reimbursement negotiations.
8:38
Unidentified speaker: The first test case is an experimental treatment in an autoimmune condition with limited treatment options.
8:43
Unidentified speaker: Novartis has been explicit that accepting lower European prices could have too great an impact on its U.S.
8:50
Unidentified speaker: business under MFN.
8:51
Unidentified speaker: Here's why this matters for American patients and not just European patients.
8:55
Unidentified speaker: The immediate concern is that European patients could face longer waits or more limited access to innovative medicines.
9:02
Unidentified speaker: But MFN also threatens the incentives that support drug development here in the United States.
9:07
Unidentified speaker: For early stage biotech companies, investors make decisions today based on the potential value of medicines that may not reach the market for another decade.
9:16
Unidentified speaker: If MFN makes that future value less predictable, it becomes harder to justify financing risky research.
9:23
Unidentified speaker: That means fewer companies funded, fewer clinical trials, and ultimately fewer new patients.
9:28
Unidentified speaker: It's hard not to look at the news out of these two companies as bad news for European patients.
9:33
Unidentified speaker: It's disappointing to see that Europe is missing its opportunity to value innovation and welcome new treatments for its population.
9:42
Unidentified speaker: But the harder question is to consider what happens across the Atlantic mean for the U.S.
9:48
Unidentified speaker: healthcare system.
9:49
Unidentified speaker: And while some champions of MFN may celebrate this kind of behavior, the reality is the pie is shrinking.
9:55
Unidentified speaker: When Novartis and Roche choose not to launch in Europe, they are foregoing revenues that, while smaller than what they might have gotten in the United States, still contribute to their ability to do RD or acquire that next upcoming biotech and eventually keep the cycle of innovation going.
10:13
Unidentified speaker: So it's without a doubt a problem in Europe, and it's something that European governments have to respond to.
10:19
Unidentified speaker: The companies are reacting exactly the way many of us expected when MFN was talked about.
10:25
Unidentified speaker: When reference pricing was put in place, they were of course going to protect their progress in the US market, which has shown a willingness to pay for medicines that actually work and have high value.
10:36
Unidentified speaker: If Europe just doesn't change its posture, though, the revenues that did come out of Europe will no longer be able to be calculated, decreasing the value of the ecosystem writ large.
10:47
Unidentified speaker: And we can't look at MFN in a vacuum.
10:50
Unidentified speaker: We're talking about MFN at the exact same time we're talking about coins and China.
10:55
Unidentified speaker: And if the long-term prognosis is to wall off China via policies like coins, as well as turn off the spigot to Europe, who is unwilling to pay for new innovation, we might be steering Europe to turn their attention not to the West, but to China, where they may be able to scoop up better deals on Me Too drugs and fast followers.
11:17
Unidentified speaker: This is a concern that we'll be talking about in our comment on coins and why MFN is changing the conversation of how we look at China altogether.
11:26
Unidentified speaker: It's one of the fundamental flaws of reference pricing, because when you import someone else's prices, you're also importing their values.
11:34
Unidentified speaker: And it seems that Novartis, Roche, and others are choosing to leave Europe behind instead of face the consequences of a European-style price control ecosystem in the US.
11:45
Unidentified speaker: It's a tough decision that, frankly, they shouldn't be forced to make.
11:49
Unidentified speaker: Today we're spotlighting some encouraging news.
11:52
Unidentified speaker: This comes from Hirobumi Niki, who leads health policy for Japan's ruling liberal Democratic Party, who recently called for fundamental overhauls of the country's cost-effectiveness assessment system.
12:04
Unidentified speaker: He argued that the current framework has become primarily a tool for cutting drug prices, rather than properly recognizing the value of innovative treatments.
12:12
Unidentified speaker: Nikki-san also supported freezing cost-effectiveness-based pricing adjustments and called for abolishing Japan's off-year drug price revisions.
12:22
Unidentified speaker: These are important developments, particularly as Japan looks to strengthen its biotech ecosystem.
12:27
Unidentified speaker: And it's exactly the case that Incubate made to Nikki-san that we need to give a signal that when a drug works and it saves costs in the long run, as well as improve patients' lives, it's something that should be cherished and valued.
12:40
Unidentified speaker: And it ties right into the MFN conversation that we had.
12:43
Unidentified speaker: We're looking forward to discussing these issues with Nikisan in a few weeks during Endpoint's Japan's biotech moment event.
12:50
Unidentified speaker: We'll include a link to register in the show notes.
12:53
Unidentified speaker: But what we're most excited about is that dialogue led to a possible policy change in Japan.
12:59
Unidentified speaker: And that's why we at Incubate take on advocacy for these small wins where policymakers open their eyes and welcome innovation, value, and the biotech ecosystem.
13:09
Unidentified speaker: And from good news out of Japan, we turn to good news right here in the United States and the favorite segment without a doubt of the show, our FDA approvals corner, where we celebrate new drugs coming to the market and changing lives for patients.
13:23
Unidentified speaker: Two notable approvals from October.
13:26
Unidentified speaker: Our first approval comes from Asahi Kase Therapeutics, which has a new treatment for HSV.
13:32
Unidentified speaker: It was approved on October 9th and goes by the name Hovilpre.
13:36
Unidentified speaker: It's a good indication of innovation in a space that hasn't seen a new mechanism of action in nearly 30 years.
13:42
Unidentified speaker: We also saw approval of HIPSAGO, approved October 20th.
13:46
Unidentified speaker: It was developed by GSK and it's a first-in-class treatment for certain adults living with chronic hepatitis B.
13:52
Unidentified speaker: Given alongside existing antiviral therapies, it offers some patients the possibility of maintaining viral control even after stopping treatment.
14:01
Unidentified speaker: These are two important advances that demonstrate continued innovation in diseases where we already have medicines.
14:08
Unidentified speaker: But for a patient who doesn't respond well to the existing medicines, this innovation is going to mean a world of difference, particularly if it means they can get off of chronic medicines.
14:18
Unidentified speaker: Not only is that good for the patient, but it also bends the cost curve on treating chronic disease over time.
14:25
Unidentified speaker: We also captured what's happening in venture capital in October.
14:28
Unidentified speaker: So let's have a quick look at investments that happened throughout the month.
14:33
Unidentified speaker: We tracked 50 investments, totaling approximately $1.14 billion into the early stage biotech ecosystem.
14:40
Unidentified speaker: It's no surprise that our friends in Massachusetts led in the month with nearly $430 million invested across seven deals.
14:49
Unidentified speaker: California had 11 deals totaling $317 million, and New York, with nearly $160 million also across seven deals.
14:57
Unidentified speaker: At the congressional district level, Massachusetts 5th district, represented by Catherine Clark, had nearly $200 million just across two deals in October.
15:07
Unidentified speaker: And it was Massachusetts 7th district, represented by Ayana Presley, that had nearly 150 million.
15:13
Unidentified speaker: These investments are a reminder that the next generation of medicines is being developed right here in communities across the country.
15:20
Unidentified speaker: And they underscore why federal policies that encourage investment, support clinical research, and create a predictable environment for drug development matter so much.
15:28
Unidentified speaker: We'll be sure in particular to follow up with representatives Clark and Presley to make sure they can see just how much dollars are flowing in to their local economy.
15:39
Unidentified speaker: And finally, before we go, a quick programming note.
15:42
Unidentified speaker: Incubate is headed to London for the Jeffries London Healthcare Conference, November 16th through 18th.
15:47
Unidentified speaker: On Tuesday, November 17th, from 3 15 to 4 p.m., I'll be moderating a panel with Fierce on what's next for U.S.
15:55
Unidentified speaker: and China biotech deal making with investors and executives who are doing these deals right now.
16:00
Unidentified speaker: It's especially timely with the coins rule out for comment.
16:04
Unidentified speaker: As a reminder, those comments are due December 7th, and it's incumbent upon the investor community to make their voice heard.
16:11
Unidentified speaker: Stick around after the event on the 17th for the networking reception.
16:15
Unidentified speaker: You can also find Incubate at our booth at the Fierce Event.
16:18
Unidentified speaker: Stop by, say hello, and scan the QR code to take our investor survey.
16:23
Unidentified speaker: It'll be the details that come out of that survey that we'll be sharing with those newly elected members of Congress.
16:29
Unidentified speaker: We'll be recording episodes on the ground, so keep an eye on this feed for conversations from London.
16:35
Unidentified speaker: That's it for this episode of the Making Medicine Podcast.
16:38
Unidentified speaker: Whatever the results of this election, the work of keeping America the best place in the world to develop new medicines continues.
16:44
Unidentified speaker: And we'll be back soon to break down what the new Congress means for biotech.
16:49
Unidentified speaker: If you'll be at Jeffries in London, come find us.
16:51
Unidentified speaker: Be sure to subscribe for future episodes.
16:54
Unidentified speaker: Thanks for listening.
16:55
Unidentified speaker: And as always, keep innovating.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3 and interpreted by Qwen3.6-35B-A3B-GGUF:UD-Q4_K_XL. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights